Analyst picks & changes
By BC Staff | Feb 26, 2007 | 8:00 AM GMT
Analyst picks & changes
| Analyst picks & changes |
| Company | Bank | Analyst | Coverage | Opinion | Wk chg | 2/23 cls |
| Aradigm (ARDM) | Merriman Curhan Ford | E. Russell McAllister | New | Buy | 13% | $1.46 |
| McAllister set a $4-$5 fair value range. He believes that ARDM’s product candidates and existing partnerships are undervalued. The company’s AERx insulin Diabetes Management System (iDMS) is in Phase III testing for Type I and Type II diabetes with data expected in 2009. Novo Nordisk (NVO) has worldwide rights. |
| Arena (ARNA) | Lazard | Matthew Osborne | New | Buy | -1% | $13.71 |
| Osborne set an $18 target. He expects a data safety monitoring board (DSMB) to recommend continuing the Phase III BLOOM trial of lorcaserin to treat obesity in 3Q07. |
| BioTie (HSE:BTH1V) | Nomura | Chris Redhead | New | Buy | -2% | €0.99 |
| Redhead thinks BTH1V
|
Read the full 1301 word article
